Basso Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-12,854
Closed -$1K 349
2022
Q3
$1K Hold
12,854
﹤0.01% 410
2022
Q2
$1K Hold
12,854
﹤0.01% 609
2022
Q1
$3K Hold
12,854
﹤0.01% 665
2021
Q4
$8K Hold
12,854
﹤0.01% 531
2021
Q3
$8K Buy
12,854
+2,096
+19% +$1.56K ﹤0.01% 473
2021
Q2
$9K Hold
10,758
﹤0.01% 488
2021
Q1
$6K Buy
+10,758
New +$7.58K ﹤0.01% 364

Other funds holding BIOTW

Basso Capital Management's BIOTW Position: Q4 2022 in Review

Basso Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q4 2022, closing a stake of 12,854 shares — an estimated $1K sold.

Basso Capital Management first reported a position in BIOTW in Q1 2021 and held it in 7 quarters. The position peaked at $9K in Q2 2021. 48 funds tracked by Wall St. Rank hold BIOTW as of Q4 2022.

  • Basso Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q4 2022 after selling out during the quarter.
  • Basso Capital Management sold 12,854 Biotech Acquisition Company Warrant shares in Q4 2022, an estimated $1K.
  • Basso Capital Management first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 7 quarters.
  • Basso Capital Management's Biotech Acquisition Company Warrant position peaked at $9K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q4 2022.

Based on Basso Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.